AP Biosciences Inc
Taipei Exchange 6945.TWO
AP Biosciences Inc Price to Earnings Ratio (P/E) on January 14, 2025: -12.20
-
AP Biosciences Inc 52-week high Price to Earnings Ratio (P/E) is -8.84 on January 16, 2024, which is 27.55% above the current Price to Earnings Ratio (P/E).
-
AP Biosciences Inc 52-week low Price to Earnings Ratio (P/E) is -14.04 on September 27, 2024, which is -15.02% below the current Price to Earnings Ratio (P/E).
-
AP Biosciences Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -11.71.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Jeng-Horng Her Ph.D. |
| IPO Date | July 14, 2023 |
| Location | |
| Headquarters | No. 508, Zhongxiao East Road |
| Employees | 37 |
| Sector | Health Care |
| Industries | |
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email